Sector analysis: Health & life sciences

Global Corporate Venturing ran a short survey of corporate venture capital investors on the impact of the Covid-19 pandemic in April.

The Eli Lilly and Genmab-backed RNA drug developer is now valued at nearly $1.5bn following a decision to refocus on a coronavirus vaccine.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Eli Lilly and Genmab-backed RNA drug developer is now valued at nearly $1.5bn following a decision to refocus on a coronavirus vaccine.

Based on research from academic schools including Princeton, Chicago and Alabama at Birmingham, the oncolytic viral therapy developer has now received more than $80m to date.

The Legend Holdings and Eli Lilly-backed cancer diagnostics technology developer floated above its range to raise $223m and its shares have since risen 40%.

Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.

Cullinan Oncology contributed to a series A round that funded the launch of a cancer drug-focused joint venture with PDI Therapeutics.

GV, a corporate venturing subsidiary of internet and technology group Alphabet, has led a $63m series A2 round for Verve Therapeutics, a US-based developer of genomic heart disease drugs.